Bio-Better Outcome On Biosimilars For FDA In Senate Funding Report
This article was originally published in The Pink Sheet Daily
Executive Summary
Pressure on agency to finalize biosimilar guidances is still there, but unlike in the House, the Senate doesn't set the deadlines.